AR034405A1 - Composiciones farmaceuticas que contienen derivados de 3-amino-azetidina, los nuevos derivados y su preparacion - Google Patents
Composiciones farmaceuticas que contienen derivados de 3-amino-azetidina, los nuevos derivados y su preparacionInfo
- Publication number
- AR034405A1 AR034405A1 ARP010101025A ARP010101025A AR034405A1 AR 034405 A1 AR034405 A1 AR 034405A1 AR P010101025 A ARP010101025 A AR P010101025A AR P010101025 A ARP010101025 A AR P010101025A AR 034405 A1 AR034405 A1 AR 034405A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alq
- radical
- cooalq
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describen composiciones farmacéuticas que contienen como ingrediente activo un compuesto derivado de la 3-amino-azetidina, de fórmula (1), en la que: R1 representa un radical -NHCOR4 o -N(R5)-Y-R6; Y es CO ó SO2; R2 y R3, idénticos o diferentes, representan ya sea un aromático elegido entre fenilo, naftilo e indenilo, estando estos aromáticos no sustituidos o sustituidos por uno o varios halógeno, alquilo, alcoxi, formilo, hidroxi, trifluorometilo, trifluorometoxi, -CO-alq, ciano, -COOH, -COOalq, -CONR7R8, -CO-NH-NR9R10, alquilsulfanilo, alquilsulfinilo, alquilsulfonilo, alquilsulfanilalquilo, alquilsulfinilalquilo, alquilsulfonilalquilo, hidroxialquilo o -alq-NR7R8; o bien un heteroaromático elegido entre los ciclos benzofurilo, benzotiazolilo, benzotienilo, benzoxazolilo, cromanilo, 2,3-dihidrobenzofurilo, 2,3-dihidrobenzotienilo, pirimidinilo, furilo, imidazolilo, isocromanilo, isoquinolilo, pirrolilo, piridilo, quinolilo, 1,2,3,4-tetrahidroisoquinolilo, tiazolilo y tienilo, que estos heteroaromáticos pueden ser no sustituidos o sustituidos por un halógeno, alquilo, alcoxi, hidroxi, trifluorometilo, trifluorometoxi, ciano, -COOH, COOalq, -CO-NH-NR9R10, -CONR7R8, -alq-NR9R10, alquilsulfanilo, alquilsulfinilo, alquilsulfonilo, alquilsulfanilalquilo, alquilsulfinilalquilo, alquilsulfonilalquilo o hidroxialquilo; R4 representa un radical -alq-SO2-R11, alq-SO2-CH=CH-R11, Het sustituido por -SO2-R11 o fenilo sustituido por -SO2-R11 o -alq-SO2-R11; R5 representa un átomo de hidrógeno o un radical alquilo; R6 representa un radical fenilalquilo, Het o Ar; R7 y R8, idénticos o diferentes, representan un átomo de hidrógeno o un radical alquilo o bien R7 y R8 forman junto con el átomo de nitrógeno al que están enlazados un heterociclo mono o bicíclico saturado que tiene 3 a 10 eslabones, que contienen eventualmente otro heteroátomo elegido entre oxígeno, azufre y nitrógeno, y que está eventualmente sustituido por uno o varios alquilo; R9 y R10, idénticos o diferentes, representan un átomo de hidrógeno o un radical alquilo, -COOalq, cicloalquilo, alquilcicloalquilo, -alq-O-alq o hidroxialquilo, o bien R9 y R10 forman junto con el átomo de nitrógeno al que están enlazados un heterociclo mono o bicíclico saturado o insaturado que tiene 3 a 10 eslabones, que contienen eventualmente otro heteroátomo elegido entre oxígeno, azufre y nitrógeno, y que está eventualmente sustituido por uno o varios alquilo, -COalq, -COOalq, -CO-NHalq, -CS-NHalq, oxo, hidroxialquilo, -alq-O-alq ó -CO-NH2; R11 representa un radical alquilo, Ar o Het; Ar representa un radical fenilo, naftilo o indenilo, que estos radicales están eventualmente sustituidos por uno o varios halógeno, alquilo, alcoxi, ciano, -CO-alq, -COOH, -COOalq, -CONR12R13, -CO-NH-NR14R15, alquilsulfanilo, alquilsulfinilo, alquilsulfonilo, -alq-NR14R15, -NR14R15, alquiltioalquilo, formilo, hidroxi, hidroxialquilo, Het, -O-alq-NH-cicloalquilo, OCF3, CF3, -NH-CO-alq, SO2NH2, NH-COCH3, NH-COOalq, Het o bien sobre 2 átomos de carbono adyacentes por dioximetileno; Het representa un heterociclo mono o bicíclico insaturado o saturado, que tiene 3 a 10 eslabones y que contiene uno o varios heteroátomos elegidos entre oxígeno, azufre y nitrógeno, eventualmente sustituido por uno o varios alquilo, alcoxi, vinilo, halógeno, alcoxicarbonilo, oxo, hidroxi, OCF3 o CF3, que los heterociclos nitrogenados están eventualmente bajo su forma N-oxidada; R12 y R13, idénticos o diferentes, representan un átomo de hidrógeno o un radical alquilo o bien R12 y R13 forman junto con el átomo de nitrógeno al que están enlazados un heterociclo mono o bicíclico saturado que tiene 3 a 10 eslabones, que contiene eventualmente otro heteroátomo elegido entre oxígeno azufre y nitrógeno y que está eventualmente sustituido por uno o varios radicales alquilo; R14 y R15, idénticos o diferentes, representan un átomo de hidrógeno o un radical alquilo, -COOalq, cicloalquilo, alquilcicloalquilo, alq-O-alq, hidroxialquilo o bien R14 y R15 forman junto con el átomo de nitrógeno al que están enlazados un heterociclo mono o bicíclico saturado o insaturado que tiene 3 a 10 eslabones, que contiene eventualmente otro heteroátomo elegido entre oxígeno, azufre y nitrógeno y que está eventualmente sustituido por uno o varios radicales alquilo, -CO-alq, -COOalq, -CO-NHalq, -CS-NHalq, oxo, hidroxialquilo, -alq-O-alq ó -CO-NH2; alq representa un radical alquilo o alquileno; los radicales y porciones alquilo y alquileno y los radicales y porciones alcoxi son de cadena recta o ramificada y contienen C1-6 y los radicales cicloalquilo contienen C3-10; un isómero óptico de tal compuesto o una de sus sales farmacéuticamente aceptables. También se describen los derivados de fórmula (1) con exclusión de los compuestos (1), en donde R2 y R3 representan fenilo, R1 representa un radical -N(R5)-Y-R6, Y es SO2, R5 es un radical metilo y R6 es fenilo. Finalmente, se describe el procedimiento para preparar dichos derivados de fórmula (1). Los compuestos (1) son útiles para tratar y prevenir desórdenes que afectan el sistema nervioso central, el sistema inmunitario, el sistema cardio-vascular o endócrino, el sistema respiratorio, el aparato gastro-intestinal y los desórdenes de la reproducción.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0002777A FR2805810B1 (fr) | 2000-03-03 | 2000-03-03 | Compositions pharmaceutiques contenant des derives de 3- amino-azetidine, les nouveaux derives et leur preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR034405A1 true AR034405A1 (es) | 2004-02-25 |
Family
ID=8847707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010101025A AR034405A1 (es) | 2000-03-03 | 2001-03-02 | Composiciones farmaceuticas que contienen derivados de 3-amino-azetidina, los nuevos derivados y su preparacion |
Country Status (35)
| Country | Link |
|---|---|
| EP (1) | EP1263721B1 (es) |
| JP (1) | JP2003525269A (es) |
| KR (1) | KR100813740B1 (es) |
| CN (1) | CN1187325C (es) |
| AR (1) | AR034405A1 (es) |
| AT (1) | ATE478840T1 (es) |
| AU (2) | AU2001237526B2 (es) |
| BG (1) | BG107057A (es) |
| BR (1) | BR0108894A (es) |
| CA (1) | CA2400138A1 (es) |
| CY (1) | CY1111075T1 (es) |
| DE (1) | DE60142890D1 (es) |
| DK (1) | DK1263721T3 (es) |
| DZ (1) | DZ3311A1 (es) |
| EA (1) | EA004649B1 (es) |
| EE (1) | EE05081B1 (es) |
| ES (1) | ES2351183T3 (es) |
| FR (1) | FR2805810B1 (es) |
| HR (1) | HRP20020710A2 (es) |
| HU (1) | HUP0300350A2 (es) |
| IL (2) | IL151209A0 (es) |
| MA (1) | MA26879A1 (es) |
| MX (1) | MXPA02008346A (es) |
| NO (1) | NO324523B1 (es) |
| NZ (1) | NZ521076A (es) |
| OA (1) | OA12221A (es) |
| PL (1) | PL365007A1 (es) |
| PT (1) | PT1263721E (es) |
| SI (1) | SI1263721T1 (es) |
| SK (1) | SK12442002A3 (es) |
| TW (1) | TWI294420B (es) |
| UA (1) | UA72319C2 (es) |
| WO (1) | WO2001064633A1 (es) |
| YU (1) | YU65902A (es) |
| ZA (1) | ZA200206916B (es) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002022579A2 (en) | 2000-09-11 | 2002-03-21 | Sepracor, Inc. | Antipsychotic sulfonamide-heterocycles, and methods of use thereof |
| FR2814678B1 (fr) * | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite |
| AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| FR2833842B1 (fr) * | 2001-12-21 | 2004-02-13 | Aventis Pharma Sa | Compositions pharmaceutiques a base de derives d'azetidine |
| US7351729B2 (en) | 2002-03-08 | 2008-04-01 | Signal Pharmaceuticals, Llc | JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers |
| NZ534757A (en) | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
| FR2837706A1 (fr) * | 2002-03-28 | 2003-10-03 | Sanofi Synthelabo | Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| WO2004013120A1 (en) | 2002-07-29 | 2004-02-12 | F. Hoffmann-La Roche Ag | Novel benzodioxoles |
| DE60322114D1 (de) | 2003-01-02 | 2008-08-21 | Hoffmann La Roche | Pyrrolyl-thiazole und ihre verwendung als inverse agonisten des cb 1 rezeptors |
| DE60330392D1 (de) | 2003-01-02 | 2010-01-14 | Hoffmann La Roche | Cb 1 rezeptor inversagonisten |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| JP2006525297A (ja) * | 2003-05-01 | 2006-11-09 | ヴァーナリス リサーチ リミテッド | 治療におけるアゼチジンカルボキサミド誘導体の使用 |
| US7485732B2 (en) | 2003-06-11 | 2009-02-03 | Merck & Co., Inc. | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| CN100368407C (zh) | 2003-06-20 | 2008-02-13 | 霍夫曼-拉罗奇有限公司 | 作为cb1受体反激动剂的2-酰氨基苯并噻唑 |
| CA2551037A1 (en) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
| KR100773650B1 (ko) | 2003-12-08 | 2007-11-05 | 에프. 호프만-라 로슈 아게 | 신규한 싸이아졸 유도체 |
| JP4436369B2 (ja) | 2004-01-28 | 2010-03-24 | エフ．ホフマン−ラ ロシュ アーゲー | スピロ−ベンゾジオキソール類およびそれらのｃｂ１アンタゴニストとしての使用 |
| WO2005077897A1 (en) * | 2004-02-17 | 2005-08-25 | Laboratorios Del Dr. Esteve S.A. | Substituted azetidine compounds, their preparation and use as medicaments |
| EP1574211A1 (en) | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| ES2324720T3 (es) | 2004-05-10 | 2009-08-13 | F. Hoffmann-La Roche Ag | Pirrol o imidazol amidas para tratar la obesidad. |
| RU2394027C2 (ru) | 2004-10-27 | 2010-07-10 | Ф. Хоффманн-Ля Рош Аг | Новые индольные или бензимидазольные производные |
| EP1812418B1 (en) | 2004-11-09 | 2010-10-27 | F. Hoffmann-La Roche AG | Dibenzosuberone derivatives |
| ATE435207T1 (de) | 2005-04-06 | 2009-07-15 | Hoffmann La Roche | Pyridin-3-carbonsäureamidderivate als cb1-inverse agonisten |
| RU2417985C2 (ru) | 2005-05-30 | 2011-05-10 | Баниу Фармасьютикал Ко., Лтд. | Новые производные пиперидина |
| US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| EP1902034B1 (en) | 2005-06-02 | 2011-03-30 | Glenmark Pharmaceuticals S.A. | Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| US20100216758A1 (en) | 2005-08-10 | 2010-08-26 | Makoto Ando | Pyridone Compounds |
| WO2006115305A1 (ja) * | 2005-08-18 | 2006-11-02 | Nissan Chemical Industries, Ltd. | スルフォニル基を有するチオフェン化合物及びその製造法 |
| JPWO2007024004A1 (ja) | 2005-08-24 | 2009-03-05 | 萬有製薬株式会社 | フェニルピリドン誘導体 |
| EP1939194A4 (en) | 2005-09-07 | 2010-12-08 | Banyu Pharma Co Ltd | AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE |
| EP1940842B1 (en) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| CA2627139A1 (en) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Novel benzoxathiin derivative |
| EP1953165B1 (en) | 2005-11-10 | 2012-02-01 | Msd K.K. | Aza-substituted spiro derivative |
| AR058199A1 (es) * | 2005-11-28 | 2008-01-23 | Merck & Co Inc | Derivados de 3- alquilazetidina sustituidos con heterociclos |
| US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
| US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
| RU2009108280A (ru) | 2006-08-08 | 2010-09-20 | Санофи-Авентис (Fr) | Ариламиноарилалкилзамещенные имидазолидин-2,4-дионы, способы их получения, содержащие эти соединения лекарственные средства и их применение |
| US7781593B2 (en) | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
| EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| CA2664358A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diarylketimine derivative |
| EP2145884B1 (en) | 2007-04-02 | 2014-08-06 | Msd K.K. | Indoledione derivative |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
| WO2009110510A1 (ja) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | アルキルアミノピリジン誘導体 |
| JPWO2009119726A1 (ja) | 2008-03-28 | 2011-07-28 | Ｍｓｄ株式会社 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体 |
| CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| AU2009261248A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
| CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| JPWO2010013595A1 (ja) | 2008-07-30 | 2012-01-12 | Ｍｓｄ株式会社 | ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体 |
| CN102264228A (zh) | 2008-10-22 | 2011-11-30 | 默沙东公司 | 用于抗糖尿病药的新的环状苯并咪唑衍生物 |
| JP5635991B2 (ja) | 2008-10-30 | 2014-12-03 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | イソニコチンアミドオレキシン受容体アンタゴニスト |
| US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US8759539B2 (en) | 2008-11-17 | 2014-06-24 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| US20120220567A1 (en) | 2009-07-23 | 2012-08-30 | Shipps Jr Gerald W | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| EP2563764B1 (en) | 2010-04-26 | 2015-02-25 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
| US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| US9006268B2 (en) | 2010-06-11 | 2015-04-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| US8410107B2 (en) | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
| AU2011316975A1 (en) * | 2010-10-22 | 2013-05-23 | Janssen Pharmaceutica Nv | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors |
| US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
| CA2826649C (en) | 2011-02-25 | 2016-07-26 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| WO2012120051A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8809324B2 (en) | 2011-03-08 | 2014-08-19 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| US20140045746A1 (en) | 2012-08-02 | 2014-02-13 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| BR112015019836A2 (pt) | 2013-02-22 | 2017-07-18 | Merck Sharp & Dohme | composto, composição farmacêutica, e, uso de um composto |
| US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| CN113388007A (zh) | 2013-06-05 | 2021-09-14 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP3186242B1 (en) | 2014-08-29 | 2021-10-06 | Tes Pharma S.r.l. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| EP3526199B1 (en) | 2016-10-14 | 2022-04-13 | Tes Pharma S.r.l. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| CN113302189A (zh) | 2018-11-20 | 2021-08-24 | Tes制药有限责任公司 | α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂 |
| EP3924058A1 (en) | 2019-02-13 | 2021-12-22 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| EP4010314B1 (en) | 2019-08-08 | 2024-02-28 | Merck Sharp & Dohme LLC | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
| JP7443625B2 (ja) | 2020-08-18 | 2024-03-05 | メルク・シャープ・アンド・ドーム・エルエルシー | ビシクロヘプタンピロリジンオレキシン受容体アゴニスト |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4242261A (en) * | 1979-07-19 | 1980-12-30 | A. H. Robins Company, Inc. | Production of methylene-cycloamines |
| FR2649100B1 (fr) * | 1989-06-29 | 1994-03-04 | Laboratorios Dr Esteve Sa | Nouvelles azetidines, leur preparation et leur application comme intermediaires pour la preparation de composes avec activite antimicrobienne |
| JPH05201971A (ja) * | 1992-01-28 | 1993-08-10 | Hokuriku Seiyaku Co Ltd | 環状アミン含有ベンゼンスルホンアミド誘導体 |
| JPH11508540A (ja) * | 1995-06-29 | 1999-07-27 | ノボ ノルディスク アクティーゼルスカブ | 新規の置換アザ環式またはアザ二環式化合物 |
| GB9714129D0 (en) * | 1997-07-04 | 1997-09-10 | Pfizer Ltd | Azetidines |
-
2000
- 2000-03-03 FR FR0002777A patent/FR2805810B1/fr not_active Expired - Fee Related
-
2001
- 2001-01-03 UA UA2002097700A patent/UA72319C2/uk unknown
- 2001-02-23 TW TW090104188A patent/TWI294420B/zh not_active IP Right Cessation
- 2001-03-01 PT PT01909938T patent/PT1263721E/pt unknown
- 2001-03-01 CN CNB018060269A patent/CN1187325C/zh not_active Expired - Fee Related
- 2001-03-01 EP EP01909938A patent/EP1263721B1/fr not_active Expired - Lifetime
- 2001-03-01 ES ES01909938T patent/ES2351183T3/es not_active Expired - Lifetime
- 2001-03-01 EA EA200200942A patent/EA004649B1/ru not_active IP Right Cessation
- 2001-03-01 AU AU2001237526A patent/AU2001237526B2/en not_active Ceased
- 2001-03-01 BR BR0108894-7A patent/BR0108894A/pt not_active Application Discontinuation
- 2001-03-01 AT AT01909938T patent/ATE478840T1/de active
- 2001-03-01 MX MXPA02008346A patent/MXPA02008346A/es active IP Right Grant
- 2001-03-01 DK DK01909938.1T patent/DK1263721T3/da active
- 2001-03-01 PL PL01365007A patent/PL365007A1/xx not_active IP Right Cessation
- 2001-03-01 NZ NZ521076A patent/NZ521076A/en unknown
- 2001-03-01 KR KR1020027011516A patent/KR100813740B1/ko not_active IP Right Cessation
- 2001-03-01 SI SI200130980T patent/SI1263721T1/sl unknown
- 2001-03-01 SK SK1244-2002A patent/SK12442002A3/sk unknown
- 2001-03-01 YU YU65902A patent/YU65902A/sh unknown
- 2001-03-01 OA OA1200200269A patent/OA12221A/fr unknown
- 2001-03-01 CA CA002400138A patent/CA2400138A1/fr not_active Abandoned
- 2001-03-01 IL IL15120901A patent/IL151209A0/xx unknown
- 2001-03-01 WO PCT/FR2001/000601 patent/WO2001064633A1/fr active IP Right Grant
- 2001-03-01 DE DE60142890T patent/DE60142890D1/de not_active Expired - Lifetime
- 2001-03-01 HU HU0300350A patent/HUP0300350A2/hu unknown
- 2001-03-01 EE EEP200200486A patent/EE05081B1/xx not_active IP Right Cessation
- 2001-03-01 JP JP2001563476A patent/JP2003525269A/ja not_active Ceased
- 2001-03-01 AU AU3752601A patent/AU3752601A/xx active Pending
- 2001-03-02 AR ARP010101025A patent/AR034405A1/es unknown
- 2001-09-07 DZ DZ013311A patent/DZ3311A1/fr active
-
2002
- 2002-08-12 IL IL151209A patent/IL151209A/en not_active IP Right Cessation
- 2002-08-28 ZA ZA200206916A patent/ZA200206916B/en unknown
- 2002-08-28 MA MA26793A patent/MA26879A1/fr unknown
- 2002-08-29 HR HR20020710A patent/HRP20020710A2/hr not_active Application Discontinuation
- 2002-09-02 NO NO20024176A patent/NO324523B1/no not_active IP Right Cessation
- 2002-09-03 BG BG107057A patent/BG107057A/bg unknown
-
2010
- 2010-10-29 CY CY20101100983T patent/CY1111075T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR034405A1 (es) | Composiciones farmaceuticas que contienen derivados de 3-amino-azetidina, los nuevos derivados y su preparacion | |
| CO5150230A1 (es) | Derivados de azetidina, su preparacion y los medicamentos que los contienen | |
| AR049739A1 (es) | Derivados de aril-piridina | |
| AR060545A1 (es) | Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas | |
| UY28132A1 (es) | Derivados de pirrolopirimidina | |
| AR036042A1 (es) | Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa | |
| JP2003506406A5 (es) | ||
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| CA2400141A1 (fr) | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation | |
| AR028952A1 (es) | Antagonistas receptores de trombina | |
| AR056321A1 (es) | COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS | |
| AR046244A1 (es) | Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos | |
| HRP20100283T8 (en) | Derivatives of n-' (1,5-diphenyl-1h-pyrazol-3-yl) sulphonamide with cb1 receptor affinity | |
| CO5560610A2 (es) | Derivados de yodobenzopiran-4-ona que tienen actividad fungicida | |
| CO5251381A1 (es) | Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR030959A1 (es) | Derivados de aminoalcoholes, procedimiento para prepararlos, el uso de los mismos para preparar medicamentos y las composiciones farmaceuticas que las contienen | |
| CO5640155A2 (es) | Derivados de pirido[2,1-a]isoquinolina como inhibidores de la dpp-iv | |
| AR058769A1 (es) | Inhibidores de peptidil-deformilasa(pdf),utiles para el tratamiento de la tuberculosis y composiciones farmaceuticas que los contienen. | |
| DE60335869D1 (de) | 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren | |
| AR036597A1 (es) | Derivados de 1h-imidazol que tienen actividad agonista de cb1, agonista parcial de cb1 o antagonista de cb1 | |
| AR051638A1 (es) | Compuestos de piperidinilo y su uso para tratar desordenes de respuesta al bloqueo de los canales de calcio tipo n | |
| AR031809A1 (es) | Quinolonas antimicrobianas, sus composiciones y usos | |
| ECSP066415A (es) | 2-carbonilamino-6-piperidinaminopiridinas sustituidas y 1-carbonilamino-3-piperidinaminobenzenos sustituidos como 5-ht1f agonistas | |
| AR054688A1 (es) | Alquil-piridinas como inhibidores 11-beta de la diabetes | |
| AR078619A1 (es) | Derivados de ciclohexano espiro-condensados como inhibidores de hsl, utiles en el tratamiento de la diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |